Founder Head our well on Kayyem. Faiz and I’m you of the today Thank R&D, CFO, all by and good our Dr. you, for joined thank as and Mendel; as Scott us. Johnny, call afternoon joining
call third will menu. us ePlex overview financial progress results the quarter. the First, for of specific then results, walk program. Faiz ePlex for details provide We’ll quarter I performance including will And through and Scott your will more then questions. regarding provide XXXX an open our finally, on our
long-term position results we strong for market, and than multiplex success talk growth believe less continued the toward initiatives is and today. I still in diagnostics accelerate progress demonstrated global to quarter third achieving penetrated. the quarter more key will the an positioning increase us I compared molecular that by But Revenues during we which $XX.X the third XXXX. Third our believe with of first, will XX% accomplishments summarizing third would start quarter call million, our about results. like in X.X% the of detail quarter were our in
ePlex Our performance was our analyzers. of highlighted by placements strong
compared the strengthen very of labs U.S. customer funnel use to opportunities to installed platform, XXX ease ePlex base XX of the in and European the remains alternatives. the global available ePlex finished countries we positive third feedback of and results we continues multiple interface reporting user in in well of quarter, and ePlex placed of In comprehensive capabilities end-user intuitive Our quarter analyzers the confirming high as the and with its quality an as analyzers.
revenue today, the some which the guidance remainder taken valuable insights Europe We the in installed with commercialization we’re color United in our the analyzers. take and to ePlex gained States, provide into XXXX. and like third through seeing margin I’d additional XXX ePlex we’ve of an to new quarter to of on account for that expect both XXX year gross minutes We’ve early the few impacted the and of dynamics field results have our efforts our to base end and in
know, the for As a of complex be can diagnostic you acquisition process system and many lengthy.
the ePlex period site XX averaged formal in for of which system to all days. implementation by In validation, ePlex the has a a this United has business with to agreement Our followed initial process process at approximately typically use. leads which previously historically of agreement States customer starts and of an an evaluation ultimately routine represented our install clinical a
in is complex Europe currently longer the in which to to two and as into is expectations difficulties from translating a some experience This experiencing in selling and European revenue We’re ePlex ePlex cycle routine generation largely driven market compared more U.S. our placement factors. a the implementation to and by
while cases Europe, longer significantly in laboratory approval in support days. is there in and excess First, is administrative strong of ePlex clinical some expected taking for and than the XXX process
yet and from anticipated, Europe. is We placements to resulting taking can administrative believe ePlex returns steps that we business. partially and in not reagent to due position to the in rest And As that a anticipated. more result had in lowering we’re in Europe the process, had consumable for meaningfully capital European The that investment rentals ePlex to revenue Europe in lower complexities than revenue is you net expectations contribution assure will to our in Europe long-term access result, emerge to more appears thereby related is market meaningful generate we started our many success than and coming of second, our continue have the company near-term better revenue. which of overall our for the on originally market the constrained,
in incredibly line world’s is with the help with molecular to the this implementation are and capture U.S. product the future. market. exceed ePlex experience of XXXX. To on adoption market Europe far in we we with expect cycle the headwinds will we about for to the foreseeable we acquisition represented more placements of our Moreover, sales in extremely third diagnostics share quarter capital relatively our the experiencing of far thus into placements, European-driven XX% quarter total in U.S. in process. our in the in in in optimistic expectations early placements Although market put are our placements in ePlex lower our than the as those are Europe, this revenues the and largest U.S. as of growth for terms in the perspective, that Overall, ePlex one offset we assumptions anticipate opportunity and U.S. the U.S., the market, pleased progress only
greater primarily result and flu by peak. as million of hesitance forward. these technology an we mix will And in are $XX of season dynamics we drive adopt during rentals overall headwinds a adjusting However, in Furthermore, volumes revenue XXXX factors customers’ reagent anticipate million. competitive are our we the new driven slowdown testing range going believe a as that a we to facing to the certain placements $XX Europe, to guidance
ePlex on to Moving our menu.
fungal quarter, these the panels of the gram-negative markers including inclusivity broadest highlighted second and We to we family we As confident drug achieved bloodstream antibiotic the multiplex in blood solution panels. infection pathogen help designed Mark address the offer they ePlex assays, identification the gram-positive, and complete the for CE and growing resistance any such of crisis on of state will molecular today, meaningfully management critical we the improve health and provide tool disease are public and highly resistance. this as a to market new culture
design our are and performance of We panels. culture the ID pleased blood with
during few some manufacturability. improve opportunities months identified we aspects past the to However, certain of their
taking for submission. are these time FDA improvements studies commencing our clinical before We implement the to necessary
timeline studies to approach than execute We revised plan and completing staggered on now and these more a concurrently. them to have our submissions also
shortly FDA ID As clinical a now result, blood studies expected now submission commence culture plan with we XXXX. midyear to
comprehensive turn that to this on reiterate committed actionable rapid, fully I our to amazing team I delivering to remains Before molecular manage patient call the to provide diagnostic over opportunity care. efficiently to and want Scott, results
across overall be Sample-to-Answer panel laboratory, used in efficiency care. multiplex but enables to differentiated improve drive proprietary also the only of technology uniquely cost effectiveness can Our reduce a help patient settings all and cost not that and outcomes workflow care
by continue energized to positive We’re ePlex. customer on feedback the we receive
is how capabilities, prior institution. identified emergency the department RP run how call of The ePlex and on recently now flows, methods. of LIS Mendel. our now to the the by workflow three physicians perfect lab One that Scott? our with is example the their turnaround and designed planning patient is optimized them to is us on shifts. having Scott is have their lab. on will are testing better shared I enthusiastic This hospitals, that, RP based handover customers panel all patient has for already the been With a would for and positive broad reduced And not impact pathogens time detected new manage helping the ePlex advanced ePlex the about
